Podcasts about alcohol use disorder

Interview with Christian S. Hendershot, PhD, and Klara R. Klein, MD, PhD, authors of Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. Hosted by John Torous, MD. Related Content: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder Semaglutide Shows Promise in Reducing Alcohol Cravings

Interview with Christian S. Hendershot, PhD, and Klara R. Klein, MD, PhD, authors of Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. Hosted by John Torous, MD. Related Content: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder Semaglutide Shows Promise in Reducing Alcohol Cravings

Send a textMany people are told recovery means lifelong struggle.What if that's not the whole story?In this episode, Katie Lain shares how the Sinclair Method helped her break alcohol's grip—not through willpower, shame, or abstinence-first thinking, but by working with the brain's reward system.As alcohol slowly lost its appeal, Katie found something deeper: peace, agency, and a spiritual awakening she never expected.Together, we explore:Why empowerment matters in recoveryHow healing the brain can open the heartWhy “losing interest” beats fighting cravingsMaking space for multiple recovery pathwaysThis conversation isn't about replacing one method with another—it's about widening the door to freedom.Support the show

Medication Availability for Alcohol Use Disorder in Substance Use Disorder Treatment Facilities JAMA Network Open This study examined the availability of medications for alcohol use disorder (MAUD) in SUD treatment facilities (SUDTF) from 2017 to 2023.  Data was obtained from SAMSA's Mental Health and Addiction Treatment Tracking Repository. The percentage of counties with a SUDTF offering MAUD increased from 34% in 2017 to 50% in 2021. This increase leveled out between 2021 and 2023 perhaps related to the pandemic. Counties with a MAUD-offering facility were more likely to be metropolitan (57% vs 25%, p

In this episode, Dr Tsen Vei Lim speaks to Professor Amandine Luquiens, a psychiatrist and addiction specialist at the University of Montpellier and the Addiction Department of Nîmes University Hospital, France. The interview covers Amandine's research article on psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial.Psilocybin and its recent popularity in clinical trials [01:22]The concerns of using psilocybin to treat psychiatric disorders [03:05]The use of psychotherapy alongside psilocybin in treatment [05:16]The key findings from the study [07:01]The contribution of the findings to policy and practice [10:13]The public's current opinion for using psilocybin for psychiatric disorders [12:07]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK).About Amandine Luquiens: Amandine Luquiens is a psychiatrist and addiction specialist, Full Professor at the University of Montpellier and the Addiction Department of Nîmes University Hospital. Her research focuses on patient-reported outcomes and psychotherapy-based interventions in addiction, with a particular interest in mindfulness and psychedelic-assisted psychotherapy; she conducted the first clinical trial in France on psychedelics. Her work also addresses alcohol use disorder and gambling disorder, including the use of account-based gambling data to inform evidence-based guidance for policymakers. She is a member of the Centre de recherche en Epidémiologie et Santé des Populations (CESP) Inserm U1018 team Primary Care, Prevention and Women's Health, and aims to advance patient-centered addiction care.Original article: Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial https://doi.org/10.1111/add.70152Author's declaration of interest: AL has no conflict of interest in the field of psychedelics. She was the recipient of a grant regulated by a public organism “French observatory of addictive behaviors- OFDT” and constraining all French monopolistic gambling service providers to redistribute 0.002% of stakes on their platforms to academic research. The gambling service provider implied in that grant was the “Paris Mutuel Urbain” (PMU). Independency of the research with no constraint on the protocol, the analysis and the publication were guaranteed by a strict convention between universities, hospitals and the PMU. AL signed a data sharing agreement for the “OSE” study, through an academic-private convention with the FDJ: Independency of the research with no constraint on the protocol, the analysis and the publication were guaranteed by a strict convention between the hospital and the FDJ, and no funding was part of the convention.The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

Cardiologist Bob Harrington talks to Mitch Elkind, chief science officer for Brain Health and Stroke at the AHA, about the heart-brain connection and why what's good for the brain is good for the heart. This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-harrington Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association  https://www.ahajournals.org/doi/10.1161/CIR.0000000000001078 Migraine Headache: An Under-Appreciated Risk Factor for Cardiovascular Disease in Women https://www.ahajournals.org/doi/10.1161/JAHA.119.014546 Cardiovascular disease patients have increased risk for comorbidity: A cross-sectional study in the Netherlands https://doi.org/10.1080/13814788.2017.1398318 Characteristics and treatment of midlife-onset epilepsy: A 24-year single-center, retrospective study https://doi.org/10.1002/epd2.20253 Traumatic Brain Injury and Risk of Neurodegenerative Disorder https://doi.org/10.1016/j.biopsych.2021.05.025 Cardiac Changes in Parkinson's Disease: Lessons from Clinical and Experimental Evidence https://doi.org/10.3390/ijms222413488 The neuropathological diagnosis of Alzheimer's disease https://doi.org/10.1186/s13024-019-0333-5 Failed Semaglutide for Early Alzheimer's Not the End of the Road? https://www.medscape.com/viewarticle/failed-semaglutide-early-alzheimers-not-end-road-2025a1000y4l Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration https://doi.org/10.1161/circulationaha.121.055018 Reduced regional cerebral blood flow in patients with heart failure https://doi.org/10.1002/ejhf.874 Heart-brain Interactions in Heart Failure https://doi.org/10.15420/cfr.2018.14.2 While You Were Sleeping, the Brain's 'Waste Disposal System' Was at Work https://www.medscape.com/viewarticle/while-you-were-sleeping-brains-waste-disposal-system-was-2025a1000mbb Repurposing Semaglutide and Liraglutide for Alcohol Use Disorder https://doi.org/10.1001/jamapsychiatry.2024.3599 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356 "VOODOO" Death https://ajph.aphapublications.org/doi/full/10.2105/AJPH.92.10.1593 Longitudinal brain ageing after stroke: a marker for neurodegeneration and its relevance for upper limb motor outcome https://doi.org/10.1093/braincomms/fcaf299 Unlocking Longevity: Aging Reimagined  https://www.medscape.com/viewarticle/1002241 You may also like: Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

Gray Area Drinking, Binge Drinking, Alcoholism, Alcohol Use Disorder or Problem Drinking? How Do You Know When Alcohol Is the Issue. In this episode of the Sober Motivation Podcast, Brad sits down with Shaz to share a raw and honest story of alcohol's role, blackouts, secret drinking, and pandemic-era daily drinking. This conversation is for anyone who doesn't see themselves as fitting with a label, but still feels uneasy about their relationship with alcohol. Shaz walks through how alcohol shifted from social use to binge drinking, how gray area drinking quietly escalated, and how secrecy, rationalization, and comparison kept him stuck for years. You'll hear why waiting for a diagnosis or label delayed real change—and how sobriety, connection, and community support became the turning point. If you're sober curious, questioning your drinking, or wondering whether life would feel better without alcohol, this conversation offers clarity, validation, and a path forward—without shame or judgment. Contact Shaz on IG: https://www.instagram.com/shazman07/  

Dr. Keith Humphreys is a professor of psychiatry and behavioral sciences at Stanford School of Medicine and a leading expert on treating addictions, drug laws and policy. We discuss all the major addictive substances and behaviors, including alcohol, opioids, gambling, stimulants, nicotine, cannabis and more, focusing on how genetics and certain use patterns shape addiction susceptibility. We discuss the best evidence-based tools for recovery, from 12-step programs to emerging treatments such as psychedelics and ibogaine. Anyone interested in making better choices for their health and/or seeking to avoid or overcome addictions ought to benefit from this episode. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman David: https://davidprotein.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Timestamps (00:00:58) Keith Humphreys (00:03:22) Addiction; Genetic Risk (00:09:14) Alcohol Use Disorder & Alcoholism; Genetic Predisposition & Addiction Risk (00:18:03) Sponsors: David & BetterHelp (00:20:37) Women & Alcohol Use; Young Adults; Cannabis Use (00:23:36) Health Benefit to Alcohol?, Red Wine, Cancer Risk; Social Pressure (00:31:47) Alcohol in Social Gatherings, Social Anxiety, Vulnerability, Work & Dates (00:37:41) Old vs New Cannabis & THC Levels; Smoked vs Edible Forms (00:44:38) Cannabis & Psychosis Risk; Cardiac Health; Youth Cannabis Use & Transition to Adulthood (00:52:29) Sponsor: AG1 (00:54:13) Industries of Addiction, Regulation; Gambling, Slot Machines, Novelty; Casinos (01:05:28) Decriminalization vs Legalization; Cannabis, Gateway Drug? (01:08:50) Psylocibin or LSD, Addiction Treatment; Microdosing, Clinical Trial Challenges (01:18:58) Sponsor: Helix Sleep (01:20:32) Brain Plasticity & Age; Ketamine, Depression, Transcranial Magnetic Stimulation (TMS) (01:28:10) SSRIs, Mass Shootings, Suicide, Side Effects; Drug Approval; Ibogaine & PTSD (01:36:10) Caffeine Addiction?; Stimulants & Rehab; Prescription Stimulants & ADHD (01:44:04) Nicotine, Mistaking Withdrawal for Benefit (01:47:24) Sponsor: LMNT (01:48:44) Tool: How to Talk to Someone with Addiction (01:55:23) Perception of Addicts, Character Defect, Pain (02:00:58) Overcoming Addiction, Immediate Rewards, AA; Addict & Co-Dependency? (02:09:53) Longterm Drug Use, Dopamine, Cues & Relapse; Social Media (02:16:21) Brain Stimulation, TMS; Homelessness, Substance Use & Rehab (02:26:11) Addiction Treatment Policy, Rehab & Insurance (02:29:08) Tool: 12-Step Programs, AA, Accessibility & Benefits (02:38:08) AA, Higher Power, Cult?; Flexibility, Tool: Open AA Meetings (02:44:38) GLP-1s, Weight Loss, Alcohol Addiction; Pharmaceutical Advertisements (02:52:39) Social Media Addiction, Tool: Avoiding Social Media Strategies (02:58:36) “Failure to Launch”, Youth, Video Games, Social Media; Recovery Pathways (03:04:13) AA as an Action Program, Tool: Try Different AA Meetings (03:08:21) Hospice, Death, Overcoming Fear of Death (03:13:54) Addiction to Escape Death?, Desire for Oblivion (03:18:11) Men vs Women & Addiction; Lying; Relapse; Fentanyl & Addiction Advice (03:24:27) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices